CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD). This and other cell-depleting approaches ...

Post-traumatic stress disorder (PTSD) is associated with an increased risk of developing systemic lupus erythematosus (SLE), with emerging evidence linking chronic psychological stress to immune ...

The leading causes of readmission among patients who received THA included sepsis (14.6%), nonseptic infections (14.8%), cardiovascular events (11.2%), and pulmonary complications (8.4%). Common ...

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...

Social determinants of health (SDH), such as socioeconomic status and educational background are factors that are ...

These manifestations are often part of the systemic activity or flare, which can be painful and have a considerable impact on quality of life,” said principal investigator Prof. Eric Morand, from ...

Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

The Very Early Diagnosis of Systemic Sclerosis (VEDOSS) criteria identify red flags as puffy fingers, abnormal nailfold ...

BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory ...

Although it did not meet the primary endpoint of dose-response relationship, when compared to placebo, enpatoran demonstrated improvements in measures of both systemic and cutaneous disease activity ...

Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the ...